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Abstract: In the last few years, interest has grown in the use of nucleic acids as an ocular therapy
for retinal genetic diseases. Recently, our research group has demonstrated that mRNA delivery
could result in effective protein expression in ocular cells following subretinal injection. Yet, although
mRNA therapy comes with many advantages, its immunogenicity resulting in hampered mRNA
translation delays development to the clinic. Therefore, several research groups investigate possible
strategies to reduce this innate immunity. In this study, we focus on B18R, an immune inhibitor to
suppress the mRNA-induced innate immune responses in two ocular cell types. We made use of
retinal pigment epithelial (RPE) cells and Müller cells both as immortalized cell lines and primary
bovine cells. When cells were co-incubated with both B18R and mRNA-MessengerMAX lipoplexes we
observed an increase in transfection efficiency accompanied by a decrease in interferon-β production,
except for the Müller cells. Moreover, uptake efficiency and cell viability were not hampered. Taken
together, we showed that the effect of B18R is cell type-dependent but remains a possible strategy to
improve mRNA translation in RPE cells.
Keywords: mRNA; retina; retinal drug delivery; innate immune system inhibition; B18R; retinal
pigment epithelial cells; Müller cells
1. Introduction
The fact that we can visualize our surroundings is a fantastic gift by nature. However,
as simple as it may seem, eyesight is a complex process comprising numerous pathways
and components. One of the key players is the retina, a nerve layer lining the back of the
eye and composed of a diversity of cell types such as Müller cells, photoreceptors (rods
and cones) and retinal pigment epithelial (RPE) cells. When light photons are absorbed
by the photoreceptors, this information is transformed into an electrical signal and by
the neuronal cells of the retina transferred to the brain via the optic nerve. Ultimately,
this continuous communication between retina and brain provides us with the ability to
see [1–3]. However, the function of the retinal cells can be hampered by an anomaly in one
or more specific genes leading to impaired vision. This can manifest itself in a variety of
ocular diseases such as Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa [4,5].
Fortunately, the accessibility and relative immune-privileged status of the eye, make it a
convenient organ for gene therapy [1,5,6].
The onset of nucleic acid gene therapy already took place in 1990, when Wolff et al.
showed that both plasmid DNA (pDNA) and messenger RNA (mRNA) are appropriate
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candidates for gene replacement or gene supplementation to treat genetic diseases [7–9].
Initially, pDNA attracted a lot of attention due to its higher stability but later on, mRNA
was recognized as an interesting competitor due to its appealing advantages compared to
pDNA. First of all, since mRNA is translated in the cytoplasm, it does not need to cross
the nuclear envelope for efficient transfection. This is especially an advantage for retinal
therapy since the retina harbors many non-mitotic cell types. Second, mRNA does not
integrate into the genome of the host cell, creating a lower risk of insertional mutagenesis.
Finally, mRNA production is straightforward and can be efficiently standardized according
to good manufacturing process conditions [7–10]. As naked mRNA is rapidly degraded
and does not easily enter cells, it needs a carrier system to optimize delivery. Currently,
different clinical trials are studying the potential of gene replacement therapy for retinal
diseases of which the majority is based on viral vectors. However, while viral vectors excel
in transfection efficiency, non-viral vectors have many merits which render them interesting
competitors for gene delivery. Indeed, their large carrier capacity, a low immunogenicity
profile and the potential to easily adapt their molecular structure make them an attractive
alternative to their viral counterpart [6,11,12]. Non-viral vectors can be divided into
different classes, such as polymer-based and lipid-based carriers, describing the origin of
their constituents [12]. Both Devoldere et al. and Patel et al. recently explored the potential
of lipid based non-viral vectors for mRNA delivery to retinal cells and showed notable
protein expression in different ocular cell types after subretinal injection in mice [12,13].
Although a lot of focus has been dedicated to the development of appropriate car-
riers for mRNA delivery, immune system activation remains an important hurdle to
overcome [7,10,14]. It has been described before that mRNA recognition can initiate
downstream signaling cascades eventually resulting in a diminished effect of the mRNA.
mRNA recognition is established by Pattern Recognition Receptors (PRRs). In the endo-
somal compartment, Toll-like receptors (TLRs) are involved in mRNA recognition where
TLR3 is assumed to recognize double-stranded RNA (dsRNA), while TLR7 and TLR8
mainly bind single-stranded RNA (ssRNA). In the cytosol, binding of mRNA is medi-
ated by other PRRs, such as RIG-I-like receptors (RLRs). Recognition of mRNA results
in the formation of transcription factors, which can in their turn initiate the production
of pro-inflammatory cytokines and type I interferons (IFNs). These substances induce a
new signaling pathway, eventually resulting in mRNA degradation, destabilization, and
diminished translation [7,10,14].
In order to avoid initiation of the innate immune reaction, several approaches have
been studied. First of all, mRNA itself can be modified by the insertion of naturally
occurring modified nucleosides—such as 5-methylcytidine or 5-methyluridine—and/or
several capping strategies. Changes in the mRNA backbone structure can help to avoid
recognition by the several receptors and successive initiation of the signaling cascades. It
has been shown before, however, that the effect of modified mRNA is cell type-dependent
and can also result in a decrease in mRNA translation [7,10,14]. An alternative strategy is
therefore to simulate the viral evasion of the immune system, by using small molecules to
inhibit or avoid immune-related proteins. Roughly, they have been divided into two main
groups, namely inhibitors that prevent production of the type I IFNs and inhibitors that
suppress the effect induced by type I IFNs. Over the last years, several of these immune
system inhibitors have been tested, however with variable results. [7,10,14,15].
In this research, we aim to evaluate the effect of the vaccinia-virus encoded protein
B18R which acts as a decoy receptor for type I IFNs. B18R has been investigated before
to improve cell viability after mRNA mediated reprogramming [10,16,17]. We wanted to
evaluate if B18R can have a positive effect on the mRNA transfection efficiency in ocular
cell types. To this end, we opted for two different cell types, i.e., Müller cells and RPE cells,
which are encountered by mRNA complexes after intravitreal and subretinal injection,
respectively [13]. In order to establish the relation between immortalized cell lines and
primary cell cultures we also tested the influence of B18R in freshly isolated bovine RPE
and Müller cells. To conclude, we evaluated the effect of B18R on the transfection efficiency
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of chemically modified mRNA. Since we used enhanced Green Fluorescent Protein (eGFP)
mRNA as cargo, transfection efficiency was evaluated via flow cytometry and compared
with the results of an ELISA assay, measuring the production of INF-β. Furthermore, we
evaluated the influence on uptake efficiency and toxicity of the treatment in each of the
different cell-types. In general, we observed a clear effect of B18R on mRNA translation in
the RPE cells which could be directly linked to a decrease in IFN-β concentration. On the
contrary, immortalized Müller cells did not show an increase in eGFP expression, nor a
production of type 1 IFNs upon mRNA delivery. Finally, similarity between immortalized
and primary RPE cells could be observed in contrast to the Müller cells.
2. Materials and Methods
2.1. mRNA and Cy®5 Labeling
Unmodified eGFP mRNA (Accession number: L29345) was purchased from Trilink
BioTechnologies (San Diego, CA, USA). For uptake experiments, the mRNA was flu-
orescently labeled with Cy®5 using the MR3700 Label IT® Nucleic Acid labelling kit
(Mirus Bio, Madison, WI, USA). Briefly, the Cy®5 label was added to the mRNA in a 1:1
(v:w) ratio. Next, the reaction mixture was incubated for 1 h at 37 ◦C followed by purifica-
tion with G50 Microspin Purification Columns (Mirus Bio, Madison, WI, USA) according
to the manual.
2.2. Cell Culture
RPE cells were purchased from ATCC (ARPE-19, ATCC® CRL-2302TM, Manassas,
VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 1% 2 mM L-glutamin, 2% penicillin/streptomycin (1000 IU penicillin and 1000 µg
streptomycin) and 10% Fetal Bovine Serum (FBS) (Hyclone®, Cramilton, UK). Cells were
cultured in an incubator at 37 ◦C in a humidified atmosphere with 5% CO2. When the
cells reached 90% confluency they were detached from the culture flask with 0.25% trypsin.
Three days before transfection, 6 × 103 cells per well were seeded in 96 well-plates.
In order to culture primary RPE (pRPE) cells, bovine eyes were obtained from the local
slaughterhouse and transported in 4 ◦C CO2 independent medium (18045070, Thermo
Fisher® Scientific, Merelbeke, Belgium). Experimental procedure for isolation of primary
RPE cells was based on the protocol of Toops et al. [18]. Eyes were cleaned by removing
extraocular tissue and disinfected by rinsing 5 times with antibiotic water (10% penicillin-
streptomycin in Phosphate-Buffered Saline (PBS) (−/−), Gibco, Paisly, UK). Removal of the
anterior segment of the eye was obtained by cutting with sharp scissors at 5 mm distance
from the limbus. After removal of the vitreous, the posterior eye cup was positioned in an
individual well of a 6 well-plate. Next, eyecups were filled with heated (37 ◦C) EDTA-PBS
(1 mM) solution and incubated at 37 ◦C in a humidified atmosphere containing 5% CO2 for
30 min. Afterwards, the retina was separated from the underlying RPE cells and choroid
with a pincet and cut at the optic nerve. The eyecup was placed in an individual well
of a new sterile 6-well plate, filled with heated (37 ◦C) 0.5% trypsin and incubated at
37 ◦C in a humidified atmosphere containing 5% CO2 for 30 min. Detachment of the
pRPE cells was obtained by pipetting repeatedly trypsin solution in the eyecup and the
final RPE cell suspension was transferred to a conical falcon tube. The cell suspension
was diluted with culture medium (DMEM supplemented with 1% 2 mM L-glutamin,
2% penicillin/streptomycin and 10% FBS) and spun at 300× g for 5 min. Supernatant was
discarded and the cell-pellet was resuspended in 10 mL pRPE cell culture medium (DMEM
supplemented with 1% 2 mM L-glutamin, 1% penicillin/streptomycin, 10% FBS and 1%
Non-Essential Amino Acids (NEAA)). The cell suspension was transferred to a T25 cell
culture flask and incubated at 37 ◦C in a humidified atmosphere containing 5% CO2. Cell
culture medium was refreshed three days post-harvesting. Three days before transfection,
6000 cells per well were seeded in 96-well plates.
The human Müller cell line, Moorfields/Institute of Ophtalmology-Müller 1 (MIO-
M1) was obtained from the UCL Institute of Ophthalmology, London, UK. The cells
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were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) GlutaMaxTM pyruvate
1 g/L glucose (Gibco Invitrogen, Paisly, UK) supplemented with 1% 2 mM L-glutamin,
2% penicillin/streptomycin and 10% FBS (Hyclone®, Cramilton, UK). Cells were cultured
in an incubator at 37 ◦C with humidified atmosphere containing 5% CO2 and passaged
at 90% confluency. Five days before transfection, 2000 cells per well were seeded in
96-well plates.
In order to culture primary Müller cell glia, bovine eyes were obtained from the local
slaughterhouse and transported in 4 ◦C CO2 independent medium (18045070, ThermoFisher®
Scientific, Merelbeke, Belgium). Eyes were cleaned by removing extraocular tissue and dis-
infected with antibiotic water (10% penicillin-streptomycin in PBS (−/−), Gibco, Paisly, UK).
Removal of the anterior segment of the eye was obtained by cutting with sharp scissors
at 5 mm distance from the limbus. After removal of the vitreous, the posterior eye cup
was filled with CO2 independent medium. The eyecup was cut in 4 equal parts and
the retina of 1 part was transferred to the gentleMACSTM Octo Dissociator (Miltenyi
Biotec, Bergisch Gladbach, Germany) containing separation medium. The latter con-
sists of Advanced DMEM (Gibco®, Paisly, UK) supplemented with 1% GLutamax and
1% penicillin-streptomycin. After dissociation, the dissociated retina was transferred to
a 40 µm filter (Corning Incorporated—Life Sciences, Durham, NC, USA) positioned on
a 50 mL conical tube and spun down at 300× g for 5 min at room temperature. The
supernatant of the falcon tube was discarded and the pellet was resuspended in 10 mL
separation medium. This washing step was repeated three times and finally the cell pel-
let was resuspended in Müller growth medium (separation medium supplemented with
10% heat-inactivated FBS (Hyclone, Cramilton, UK) and 4 ng/mL epidermal growth factor
(Sigma-Aldrich, Bornem, Belgium). The cell suspension was transferred to a CellBIND®
T75 flask (Sigma-Aldrich, Bornem, Belgium) and incubated at 37 ◦C in a humidified atmo-
sphere containing 5% CO2. The cell culture medium was repeatedly refreshed after 1 week.
When the cells were cultured for 3 weeks, they were passaged by 0.25% trypsin in T75 cell
culture flasks. Five days before transfection, 2000 cells per well were seeded in Corning®
96-well CellBIND® microplates.
2.3. mRNA Transfection and B18R Treatment
The 60 kDa recombinant vaccinia virus protein B18R was purchased from ThermoFisher®
(ThermoFisher® Scientific, Merelbeke, Belgium) dissolved in PBS with a concentration of
0.5 mg/mL. Cell medium was supplemented with B18R at a concentration of 150 ng/mL
simultaneously with eGFP mRNA transfection. In order to evaluate the effect of B18R on
eGFP mRNA expression, a suboptimal concentration of 0.05 µg/well mRNA was used.
Therefore, mRNA was complexed with LipofectamineTM MessengerMAXTM (ThermoFisher®
Scientific, Merelbeke, Belgium) at a cationic lipid-to-mRNA ratio of 3:1 (v:w). After trans-
fection, cells were incubated at 37 ◦C in a humidified atmosphere containing 5% CO2 for
24 h. Fluorescence signal of Cy®5 and eGFP, for uptake and transfection experiments
respectively, were measured by flow cytometry.
2.4. Flow Cytometry
After 24 h incubation with B18R and mRNA loaded lipoplexes, cell culture medium
was removed and cells were washed once with 100 µL PBS (−/−) per well. Next, detach-
ment of the cells was obtained by addition of 0.25% trypsin-EDTA (Gibco, Paisly, UK).
After 5 min incubation at 37 ◦C, the trypsin was neutralized by adding 100 µL cell culture
medium and the well plate was centrifuged at 500× g during 5 min. The supernatant was
removed and cells were resuspended in flow buffer (PBS (−/−) supplemented with 0.1%
sodium azide and 1% bovine serum albumin). Fluorescence signals were measured by
using a CytoFlex (Beckman Coulter, Suarlée, Belgium) flow cytometer and data analysis
was performed with FlowJoTM software 10.5.3 (Treestar Inc., Ashland, OR, USA).
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2.5. MTT Assay
The viability of all cell cultures was evaluated with the MTT-assay, 24 h post-transfection
with mRNA and B18R. First, cell culture medium was removed and replaced by fresh cul-
ture medium including 5 mg/mL 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) reagent (Sigma-Aldrich, St. Louis, MO, USA) at a ratio of 1:9 (MTT reagent:
culture medium). Next, the cells were incubated for 2 h at 37 ◦C in a humidified atmo-
sphere containing 5% CO2. After incubation, the solution in the wells was removed and
100 µL DMSO (Sigma-Aldrich, St. Louis, MO, USA) was added to the cells to dissolve
the formazan crystals. The well-plate was covered with aluminum foil and positioned on
an orbital shaker (Rotamax 120, Heidolph, Germany) for 30 min at 1200 rpm. Lastly, the
absorbance was measured at 590 nm and 690 nm (background) with a VICTOR3 1420-012
multilabel microplate reader (Perkin Elmer, Groningen, The Netherlands).
2.6. ELISA Assay
Supernatant of all cell types was collected 24 h after mRNA and B18R transfection
and stored at −20 ◦C. The production of IFN-β and IFN-α was determined using the
Human IFN-β ELISA kit (ThermoFisher® Scientific, Merelbeke, Belgium) and the Human
IFN-α kit (ThermoFisher® Scientific, Merelbeke, Belgium) according to the manufacturer’s
instructions.
2.7. Statistical Analysis
All data are the result of 3 independent experiments, unless declared otherwise, and
are presented as mean ± standard deviation. Statistical analysis was performed with
Graphpad Prism 8 software (San Diego, CA, USA). Analysis was performed by comparing
the test samples with a single control group transfected without B18R addition, using
a one-way ANOVA test followed by the Bonferroni post hoc test. Asterisks are used to
illustrate statistical significance (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).
3. Results
3.1. Influence of B18R Treatment on Transfection Efficiency
The vaccinia virus-encoded protein B18R has often been used in cell reprogram-
ming studies and has shown its capability to increase mRNA translation in different cell
types [7,10,16,19–21]. Since mRNA is currently making progress as a potential therapeutic
nucleic acid for retinal diseases, we explored the potential of B18R as an innate immune
inhibitor in four ocular cell types: ARPE-19 cells, MIO-M1 cells, primary bovine RPE cells,
and primary bovine Müller cells. B18R was added to the cell medium and cells were si-
multaneously transfected with mRNA-MessengerMAX lipoplexes containing a suboptimal
mRNA concentration.
As depicted in Figure 1, an increase in mRNA transfection efficiency can be observed
for all cell types, except for the MIO-M1 cells. Moreover, an obvious resemblance between
the ARPE-19 cells and primary bovine RPE cells can be noticed. Indeed, co-incubation
with B18R increased the mean fluorescence intensity (MFI) in both cell types on average
2, 5 times. Statistical significant difference in % eGFP expression between cells treated with
or without B18R was found, although a substantial increase cannot be noticed. Overall, we
can conclude that for both types of RPE cells B18R is capable of increasing the degree of
mRNA translation on average per cell without altering substantially the overall percentage
of cells transfected.
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Figure 1. Transfection efficiency of mRNA-MessengerMAX lipoplexes when co-incubated with 
B18R. (A) Data are expressed as relative percentage enhanced Green Fluorescent Protein (eGFP) 
positive cells and relative Mean Fluorescence Intensity (MFI) both normalized to the average value 
of the control group which received only mRNA-MessengerMAX complexes (eGFP) (n = 3 × 3). 
Other samples represent untreated cells (Blank) or cells co-incubated with Phosphate-Buffered 
Saline (eGFP + PBS) or B18R (eGFP + B18R) during transfection. Mean absolute % of eGFP positive 
cells for the control group was 81%, 85%, 85% and 79% for the ARPE-19 cells, MIO-M1 cells, pri-
mary bovine RPE cells and primary bovine Müller cells respectively (** p < 0.01; *** p < 0.001; **** p 
< 0.0001). (B) Data represented as histograms obtained by flow cytometry. 
Figure 1. Transfection efficiency of mRNA-MessengerMAX lipoplexes when co-incubated with B18R. (A) Data are expressed
as relative percentage enhanced Green Fluorescent Protein (eGFP) positive cells and relative Mean Fluorescence Intensity
(MFI) both normalized to the average value of the control group which received only mRNA-MessengerMAX complexes
(eGFP) (n = 3 × 3). Other samples represent untreated cells (Blank) or cells co-incubated with Phosphate-Buffered Saline
(eGFP + PBS) or B18R (eGF + B18R) during transfection. Mean absolute % of eGFP positiv cells for the control group was
81%, 85%, 85% and 79% for the ARPE-19 cells, MIO-M1 cells, primary bovine RPE cel s and primary bovine Müller cells
respectively (** p < 0.01; *** p < 0.001; **** p < 0.0001). (B) Data repres nted as histograms obtained by flow cytometry.
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In contrast to the RPE cells, the resemblance in transfection efficiency between MIO-
M1 cells and primary bovine Müller cells was missing. Intriguingly, we did not see a
difference in transfection efficiency between MIO-M1 cells transfected with or without
B18R addition. However, in the primary Müller cells, B18R did enhance transfection
efficiency, though less extensive than for the RPE cells. The MFI increased on average
1.7 times while the percentage of eGFP positive cells did not increase considerably, although
it was considered statistically significant. At last, it must be noted that the addition of PBS,
the B18R solvent, did not alter the MFI in any cell type which guarantees that the increase
in MFI is exclusively due to B18R.
3.2. Influence of B18R Treatment on Uptake Efficiency
Since we could observe a clear increase in effect for three out of four cell types, we
wanted to investigate if the same trend was visible for uptake efficiency. Cy®5 labeled
mRNA complexed with MessengerMAX was administered to the cells, whether or not in
combination with B18R. 24 h after transfection the Cy®5 signal was determined by means
of flow cytometry. Results depicted in Figure 2 show that the degree of uptake with or
without B18R was rather the same. Except for the primary bovine Müller cells, a small but
significant increase in the MFI was visible. Although when we compared this with the
order of eGFP-MFI-increase it is clear that the latter could not be completely defined by
an enhanced uptake. These data corroborate that rather than uptake, the effect of B18R
is linked to intracellular processes. We hypothesize that the effect is mainly due to the
decrease in innate immune system related type 1 IFNs concentration.
3.3. Influence of B18R Treatment on Type 1 IFN Production
Since B18R is classified as an innate immune inhibitor, we wanted to confirm if we
could detect a decrease in type 1 IFNs secretion in the supernatant of the ocular cell
types after transfection. All four cell types were transfected with mRNA-MessengerMAX
lipoplexes alone or accompanied by simultaneous addition of B18R. 24 h after transfection,
the supernatant of the cells was collected and preserved at −20 ◦C until the ELISA assay
is carried out. We opted to determine the IFN-α and IFN-β concentration, as they are
two classes of the type 1 IFNs and they are important factors in the innate immune
reaction [7,10].
As depicted in Figure 3A, transfection of ARPE-19 cells with mRNA led to an exten-
sive IFN-β production. More specifically, this resulted in a concentration of ~1409 pg/mL
IFN-β in the supernatant of the cells. This confirmed that unmodified mRNA is indeed
immunogenic and can hence efficiently trigger innate immune responses. However, pos-
sible partial immune stimulation by the carrier itself should also be taken into account.
As displayed in Figure 3B, co-administration with B18R resulted in a spectacular drop in
IFN-β concentration. In fact, the IFN-β concentration was lower than the limit of detection
(LoD) of the ELISA assay. Since the control groups receiving PBS instead of B18R showed a
small but significant increase in IFN-β concentration, we can guarantee that the decrease
in IFN-β concentration is not owing to the B18R solvent.
In contrast to the ARPE-19 cells, IFN-β production could not be induced by addition
of mRNA-MessengerMAX lipoplexes to the MIO-M1 cells. Evidently, we could also not
observe a decrease in IFN-β concentration after addition of B18R to the cells. All values
of both control groups and test groups were lower than the LoD of the ELISA assay as
depicted in Figure 4.
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Figure 4. IFN-β production of MIO-M1 cells transfected with mRNA-MessengerMAX lipoplexes with or without B18R
co-incubation as determined by ELISA (n = 3 × 3). (A) Absolute INF-β concentration in the supernatant 24 h following
transfection of MIO-M1 cells with mRNA-MessengerMAX complexes without B18R addition. (B) IFN-β concentration,
normalized to the group solely receiving mRNA-MessengerMAX complexes (eGFP), in the supernatant of MIO-M1 cells
24 h after transf ti it - essengerMAX complexes with or out B18R ad ition. The lowest concentration of
IFN-β that could be detected wi the sed ELISA assay (LoD) was 50 pg/mL. Concentrations b low the LoD are ssigned
with #. Both graphs contain a positive control with a concentration of 50 pg/mL derived from the standard curve obtained
during the experiment.
An ther class of type 1 IFNs is IFN-α of which the concentration can also be deter-
mined by ELISA assay. An id ntical exp rimental set-up as for IFN-β was u ed. Results
of these exp rimen s are depicted i Figures 5 and 6 for the ARPE-19 and IO-M1 cells
respectively. Unfortunately, for both the ARPE-19 cells and the MIO-M1 cells the IFN-α
concentration in the cell medium was below the LoD of the ELISA assay. Consequently, a
decrease in IFN-α concentration after B18R addition to the cells was impossible to observe.
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3.4. Influence of B18R on Cell Viability
Since B18R has shown to be a potential candidate for improving mRNA translation
by reducing the innate immune system response after administration, it was interesting
to evaluate its effect on cell viability. The degree of cytotoxicity was determined by MTT
Pharmaceutics 2021, 13, 74 11 of 18
assay 24 h after incubation of the cells with MessengerMAX complexed mRNA, whether
or not in combination with B18R. Results of these experiments are depicted in Figure 7 for
all cell types.
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relative cell viability normalized to the untreated control group (BLANK) which did not receive any treatment. (n = 3 × 3).
Cell viability after supplementation of the cell medium with B18R is compared to the
cell viability of the control group only receiving mRNA-MessengerMAX complexes. As
depicted in Figure 7, a significant decrease in cell viability for cells treated with mRNA-
MessengerMAX lipoplexes was observed when compared to the untreated cells. However,
B18R did not lower the viability of any of the cell types studied in this research any further.
Moreover, we did not notice substantial morphological changes between cells treated with
or without B18R (data not shown). In contrast to what is reported in some studies, we did
not observe an increase in cell viability upon B18R delivery to the cells. Finally, we could
learn from this experiment that PBS did not induce any significant increase or decrease in
cell viability. Again, this contributes to the conclusion that the effects we observed were
solely due to B18R. Taken together we can conclude that no extensive cell death is observed
after B18R treatment.
4. Discussion
mRNA made progress as a potential therapy for ocular genetic diseases but its pro-
found immunogenicity still hampers the translation to the clinic. The induced innate
immune response can result in decreased mRNA translation and/or increased mRNA
degradation. Therefore, several strategies have been developed to block these undesirable
effects. Some studies reported the effect of small molecule innate inhibitors on mRNA
translation, yet with varying results [7,22–27]. One of these inhibitors is B18R which
can be defined as a non-species-specific decoy receptor present in its soluble form in
Pharmaceutics 2021, 13, 74 12 of 18
the cell medium or on the cell surface. Upon binding, type 1 IFNs are neutralized and
both autocrine and paracrine transmembrane signaling is prevented [28–30]. A simplified
schematic overview of intracellular pathways activated upon TLR-mRNA binding and
working mechanism of B18R is presented in Figure 8. With the aim of improving mRNA
translation efficiency, we wanted to evaluate the influence of B18R in different ocular cell
types. In this regard, we delivered mRNA-MessengerMAX lipoplexes to ARPE-19 cells,
MIO-M1 cells, primary bovine RPE and Müller cells with or without the addition of B18R
to the cell culture medium. Transfection efficiency was always compared with cells only
receiving mRNA-MessengerMAX lipoplexes. Furthermore, uptake efficiency, cell viability
and type 1 IFN production were determined by flow cytometry, MTT assay and ELISA
assay respectively.
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became very attractive for investigation of biological processes and cellular responses to 
certain stimuli. Indeed, they are very cost-effective, easy to manipulate and can be cul-
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lations and therefore free of contamination [34]. However, it is worth mentioning that the 
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Figure 8. Simplified representation of intracellular pathways activated upon TLR activation and working mechanism of
B18R. Activation of TLRs leads to interaction with adaptor molecules TRIF and MYD88. Initiation of successive pathways
results in activated transcriptions factors (IRF3, IRF7 and NF-κB) causing production of type 1 IFNs and pro-inflammatory
cytokines. Type 1 IFNs in their turn can activate IFN receptors in an autocrine or paracrine fashion. Activation of IFN
receptors leads to the production of IFN-stimulated genes (ISG) via the JAK-STAT pathway. ISG can lead to production
of proteins included in the signaling pathways (not shown) or proteins inducing mRNA damage or diminished mRNA
translation. ssRNA, single-stranded ; ds RNA, double-stranded RNA; TLR, Toll-like recept r; TRIF, Toll-IL-1 receptor
domain-containing adapter prot in inducing IFN-β; MYD88, myeloid differentiation primary respo se protein 88; IRF,
interferon regulatory factor; NF-kB, nuclear fact r-κB; IFN, type 1 interferon; JAK-STAT, Janus kinase 1- Signal transducer
activator of transcription; ISG, IFN-stimulated genes; OAS, 2’-5’-oligoadenylate synthetase; ADAR, RNA-specific adenosine
deaminase; PKR, dsRNA dependent protein kinase.
As mentioned above, we made use of two immortal cell lines, ARPE-19 and MIO-M1,
as a model for the human primary RPE and Müller cells [31–33]. These two ocular cell
types are important in retinal homeostasis and encountered by medicines delivered via
subretinal or intravitreal injection [11,13]. Due to several advantages, immortal cell lines
became very attractive for investigation of biological processes and cellular responses to
certain stimuli. Indeed, they are very cost-eff ctive, easy to manipulate and can be cultured
for an extended tim . In addition, purchased cell lines are normally pure cell populations
and therefore free of contamination [34]. However, it is worth m ntioning that the latter
s ems to be not co pletely true as res arch has shown tha cell type misidentification is
highly present. A relevant drawback i t at cells in ulture can be subje ted to mutations
and chromosome alterations which can change their phenotype [35,36]. Taken together,
commercial cell lines can be a convenient model for fundamental experiments but it can
be useful to validate observations in primary cell types. For this reason, we opted to test
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the B18R treatment in two primary bovine cell types. Therefore, we could as well assess if
interspecies differences are present.
First, we assessed the influence of B18R on transfection efficiency in the four ocular
cell types described above. All cell types, except the MIO-M1 cells, showed an increased
MFI after B18R treatment as depicted in Figure 1. Although B18R has a defined working
mechanism and we are not the first research group to study its effect on mRNA translation,
an increase in transfection efficiency is not always guaranteed [16,21,37]. Contradictory
results have been described in several studies where B18R was delivered, mainly for re-
programming purposes. Yoshioka and co-workers transfected Human Foreskin Fibroblast
(HFF) cells with a combination of GFP-encoding self-amplifying mRNA and B18R-mRNA.
An increased GFP expression was noted when compared to the cells transfected with solely
self-amplifying mRNA. Furthermore, due to B18R the duration of expression could be
prolonged up to 7 days, necessary for effective reprogramming. Finally, they observed the
same effect when the HFF cells were transfected with reprogramming factors-encoding
self-amplifying mRNA and B18R-mRNA [20]. In contrast, Awe et al. did not notice an
enhanced OCT4 expression when the encoding mRNA was delivered together with the
B18R protein in human fibroblast cells. Even after using high concentrations of both B18R
or mRNA, the increase in effect was missing [27]. Similarly, Drews et al. did not notice a
decrease in innate immune system-related gene expression due to B18R or any of the other
small molecules tested. Evidently, an upregulation in reprogramming gene expression was
missing [28]. There are several studies describing the use of B18R alone or combined with
other vaccinia virus proteins during transfection with reprogramming factor-encoding
mRNA. However, no comparison is made in terms of transfection efficiency when B18R is
not used. Lastly, in this regard Zangi and colleagues were the first research group to use
B18R in vivo, injecting modified mRNA in a mouse myocardial infarction model [38]. As
mentioned before, the ARPE-19 cell line showed high similarity with the primary bovine
RPE cells in terms of transfection efficiency increase. To our knowledge, we are the first
group to ever compare these two cell types in terms of B18R influence on mRNA transfec-
tion efficiency. Since both cell types are of different origin these results are quite interesting.
Although immortalized and primary RPE cells showed high similarity, this was completely
absent for the MIO-M1 cell line and the primary bovine Müller cells. This difference can be
explained by several possible reasons which are described below.
Since B18R did not affect uptake efficiency of mRNA lipoplexes (Figure 2), the changes
in transfection efficiency were highly likely due to intracellular processes and considering
the clearly defined working mechanism of B18R we quantified the IFN-β concentration
after B18R addition by means of an ELISA assay. Since ELISA assays are dependent
on the origin of the cells used, we opted to test the two human cell lines for the IFN-β
concentration present in the cell supernatant. To our knowledge, only Beissert et al. and
Liu et al. showed the correlation between hampered IFN-β concentration and increased
mRNA translation before [39,40]. Beissert and colleagues delivered the mRNA encoding for
vaccinia virus proteins E3, K3 and B18R together with GFP-mRNA to HFF cells and showed
that increased mRNA translation was clearly correlated with a tremendous decrease in
IFN-β and OAS1 production. The enhanced expression of mRNA was also seen when the
experiments were repeated in vivo [40]. The more recent study of Liu et al. validated the
effect of B18R in HFF and HepG2 cells on mRNA transfection efficiency. However, they saw
that NS1-TX91, a protein encoded by the eight mRNA segment of the influenza A virus,
could induce a higher increase in effect and decrease in IFN-β production than B18R [39].
In this study, we showed that mRNA transfected ARPE-19 cells produce a high amount
of IFN-β which is reduced to below the LoD after B18R administration. Therefore, we
confirmed that the increase in transfection efficiency could be indeed directly correlated
to a diminished IFN-β concentration. Considering the striking similarity in transfection
efficiency between the human ARPE-19 and primary bovine RPE cells we suspect that a
similar increase in IFN-β is present in the bovine RPE cells. Earlier studies described that the
retinal pigment epithelium is a first line defense mechanism for pathogens, plays a pivotal
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role during infection to maintain the blood-retinal-barrier and can act as antigen presenting
cells (APC). Furthermore, it has been shown that RPE cells play a role during infection and
in the ocular innate immune reaction as they express several TLRs and can secrete several
cytokines and type 1 IFNs in response to certain stimuli [41–44]. Kumar M. and co-workers
were the first research group to define the expression of TLR1-7, 9 and 10 in human RPE cell
cultures with real-time PCR. However, they only focused on the TLR3 signaling in detail
since this TLR recognizes dsRNA which is an important feature of RNA viruses. When
the human RPE cells were transfected with a dsRNA analog, they noticed that secretion of
IFN-β but also Interleukin-6 (IL-6), IL-8, MCP-1 and sICAM-1 was induced. Due to the fact
that they can act as APC and express TLR3, they show a lot of similarity with dendritic cells
(DCs) although the latter also produce IFN-α upon activation [41]. However, the primarily
ssRNA we delivered is not recognized by TLR3 but by TLR7/8 which triggers the MYD88
activator molecule transmitting the signal. This results in expression of several transcription
factors which can initiate the production of type 1 IFNs and inflammatory cytokines [7,10].
Taken together, we can conclude that our results regarding IFN-β production are in line
with previous reports in literature. Despite a clear presence of IFN-β observed after
mRNA delivery to the ARPE-19 cells, they failed to produce IFN-α in reaction to the same
stimulus. The lack of IFN-α production might not seem completely surprising as IFN-α
is mainly excreted by plasmacytoid dendritic cells upon infection with mRNA or pDNA
viruses [45]. However, several reports suggest that IFN-α might also be secreted by other
cell types depending on the immune stimulus [46,47]. Kumar et al. previously showed that
delivery of a dsRNA analog to human RPE cells induced the secretion of IFN-β but not of
IFN-α. They attributed the lack of IFN-α production to the origin of RPE cells, the neural
ectoderm, which is different from DCs derived from bone marrow and do express both
IFN-β and IFN-α upon activation. They however only focused on TLR3 signaling since
they found that TLR3 was one of the most highly expressed TLRs in RPE cells [41]. In light
of our differing experimental conditions, i.e., primarily ssRNA and ordinarily activation
of TLR7/8, production of IFN-α was not ruled out in our study. To elucidate which other
possible cytokines are secreted and which TLRs are expressed to evaluate similarity with
human RPE cell cultures further extensive analysis with immunohistochemistry, PCR, flow
cytometry and/or Western blotting can be performed [48].
Although the ARPE-19 cells show a high production of IFN-β upon activation by
mRNA, the opposite is true for the MIO-M1 cells. Here we could observe that there is no
IFN-β production visible when mRNA is delivered to the cells. Hence, it was impossible to
note a decrease in IFN-β concentration and therefore an effect of B18R. The reason why
MIO-M1 cells did not produce IFN-β is not completely clear and somewhat surprising
since it has been reported that Müller cells play an important role in innate immunity [42].
Kumar et al. was the first research group to elucidate the location and function of TLRs 1-10
in MIO-M1 glia, primary murine Müller cells and a mouse retina with RT-PCR. Furthermore,
they demonstrated the presence of adaptor molecules MYD88, TRAM and TRIF which
are important for activation of the signaling pathways. Finally, they detected an increased
concentration of several cytokines and MAPKs of the NF-κB pathway after activation with
TLR agonists. However, they did not evaluate type 1 IFN secretion or the presence of
signaling molecules linked to other pathways. The group did show activation of TLR3,
TLR7 and TLR9 after stimulation, showing that the Müller cells indeed have a role in innate
immunity [48]. Additionally, other research groups described the production of several
different cytokines by the MIO-M1 cell line and the gliotic retina [49–51]. Interestingly,
we did see an increase in effect in the primary bovine Müller cells suggestive of IFN-β
neutralization by B18R. This contrast with the MIO-M1 cell line can be explained by several
factors. As described above, cell contamination might be a problem with immortal cell
lines but can also happen while culturing the primary cells from a bovine retina. Although
the purification protocol is partially selective and morphology of cells was evaluated before
continuation of experiments, there is never 100% assurance that the final culture will only
consist out of Müller cells. The contaminating cells, such as astrocytes, can possibly interfere
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with the results [33]. Another option is that there are intracellular differences between
the MIO-M1 cells and primary bovine Müller glia. The latter are not only from another
origin but might also be exposed to more stress than MIO-M1 cells, as described for rat
primary Müller cells before [33]. This can possibly influence their reaction to components
delivered to the cell. Similar to the ARPE-19 cells, no IFN-α production could be noticed
after mRNA delivery to the MIO-M1 cells. Previous research showed that both IFN-α
and IFN-β production could be stimulated in Müller cells both in vitro and in vivo after
exposure to the herpes simplex virus type 1 [52]. However, the Herpes Simplex virus is a
DNA virus and thus activates the immune system via the TLR9 and not via the TLR7/8
which may explain the difference in result [53,54]. Furthermore, we worked with a human
immortal cell line and primary bovine Müller cells which are from a different origin than
the Müller cells tested in the study of Drescher et al. These aspects might influence the
outcome of experiments and therefore explain the difference of our study with results
reported in literature regarding IFN-α production. However, since Kumar et al. showed
presence of TLR7 in MIO-M1 cells, one would expect the production of type 1 IFNs after
mRNA delivery [48]. We hypothesize that possibly one of the key players in the type 1
IFN-signaling cascade, such as IRF7, is not expressed. Further immunology research can be
useful to detect if and which pathway and signaling molecules are activated upon mRNA
delivery to MIO-M1 cells.
Finally, we evaluated the effect of B18R on the viability of the four different cell types.
It has been reported before that B18R addition to the cell culture medium can improve
cell viability after mRNA transfection [16]. We assume that this is also the reason several
researchers use B18R in reprogramming studies with modified mRNA without comparison
with the situation where no B18R is used [16,21,37,38]. Our results demonstrated no
substantial changes in cell viability after treatment with B18R. Due to the difference with
previously published results, we believe the reported increase in viability might be cell
type-dependent. Furthermore, a more recent study showed that the increase in HFF
cell viability due to B18R was only visible after multiple mRNA transfections [30]. This
could also explain why we do not see a considerable increase in cell survival after one
mRNA transfection.
5. Conclusions
In this study, we have proven that B18R can increase mRNA translation in ocular cell
types. Since the increase in effect is mainly present in the RPE cells, both in the immortal
cell line as the primary cells, the vaccinia virus protein can be primarily interesting as
adjuvant during subretinal injections. Due to the presence of B18R, the concentration of
the mRNA to be delivered can be downscaled while maintaining the same level of effect.
This provides possibilities to reduce the degree of side effects that may occur. Although
extensive immunology research was beyond the scope of this study, future tests on Müller
cells to identify the signaling molecules activated and cytokines secreted upon mRNA
delivery, can be interesting to elucidate the pathways that are induced and gain more
knowledge about the intracellular processes that are involved. After all, the Müller cells
remain an important cell type in the retina also reachable with the less invasive intravitreal
injection technique. Additionally, possible added value of other vaccinia virus proteins
could be evaluated and TLR expression analysis in primary bovine cells can be performed
to elucidate resemblance with the immortal cell lines and estimate their potential as a good
ex vivo model for retinal studies. At last, studying the effect of B18R on expression of
mRNA encoding for a therapeutic protein of interest in the appropriate models would give
us insight into its potential to become a clinically relevant therapy
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